Latest News
A single gene insertion of green opsin into the eyes of blind mice has allowed them to regain sight, according to a recently published study.
Results of a recent study indicate that regular consumption of mushrooms may decrease the risk of mild cognitive impairment.
Researchers have revealed that a stroke could alter an individual’s microbiome even up to 1 month after it occurs; this has emphasized the importance of incorporating gut health in patient recovery and treatment.
Journal Articles
In this report from Future Neurology, researchers describe the application and state of development of a range of CSF biomarkers in common neurodegenerative disorders.
In this review from Biomarkers in Medicine, researchers demonstrate that PARK7 and NDKA could present more clinical important information as biomarkers for management of stroke disease.
Take a look behind the scenes of a recent CNS Oncology paper as we ask the authors about the Nativis Voyager® for the treatment of glioblastoma.
Autoimmune
Could hyaluronic acid contribute to chronic white matter injury?
Can living in a sunnier climate in your youth reduce the risk of MS?
Cerebrovascular disease
Stroke recovery: could the microbiome be a new therapeutic option?
The obesity paradox: could excess body fat improve stroke survival rates?
Role of PARK7 and NDKA in stroke management: a review of PARK7 and NDKA as stroke biomarkers
CNS/PNS/SNS
Does ‘broken heart’ syndrome originate in the brain?
3D printed scaffold promotes nerve cell growth for spinal cord injury
Advances in enteric neurobiology – the ‘brain’ in the gut in health and disease
Cognitive/neurodegenerative disorders
Could mushrooms prevent cognitive decline?
Could an eye scan detect signs of Alzheimer's disease?
Alzheimer’s disease: hormone therapy linked to small risk increase
Demyelinating disease
Multiple sclerosis: determining the dynamic nature of oligodendrocyte regeneration
Biomarker discovery and development in multiple sclerosis: where are we now?
US FDA warns of stroke risk with multiple sclerosis drug: industry news round-up
Development and pediatrics
Is there a link between vitamin D deficiency and loss of brain plasticity?
US FDA warns of stroke risk with multiple sclerosis drug: industry news round-up
Gilenya® gains EMA approval for pediatric multiple sclerosis
Epilepsy and seizure
Wireless ‘pacemaker for the brain’ could treat tremors and seizures in neurological diseases
Cannabidiol for epilepsy expected to be available within 6 weeks: industry news round-up
Genetics
Ask the Experts: Gene therapies in neurological diseases (Part II: challenges and future outlooks)
Ask the Experts: Gene therapies in neurological diseases (Part I: development, design and delivery)
SfN18: The potential of gene therapy in neurological disorders
Headache
US FDA warns of stroke risk with multiple sclerosis drug: industry news round-up
Alzheimer’s drug development halted following toxic reaction: industry news round-up
Aimovig® receives EMA license for the prevention of migraine
Immune disorders and inflammation
Inflammatory disease and anxiety: could endocannabinoids be a mechanism of comorbidity?
FENS 2018: Immune system offers new way of treating Alzheimer’s disease
FENS 2018: Could anxiety and inflammation be treated with cannabis?
Infection
Link between Alzheimer’s disease and periodontal bacteria gains traction
Injury/trauma
World’s first iPS trial approved in Japan for spinal cord injuries
‘Punch drunk syndrome’: an early career perspective with Marc Goldfinger
‘Punch drunk syndrome’: an introduction to CTE, clinical relevance and pathology
Movement disorders
Groundbreaking Parkinson’s trial offers hope for restoring damaged brain cells
Wireless ‘pacemaker for the brain’ could treat tremors and seizures in neurological diseases
RESTORE-1: first patient dosed with gene therapy in Parkinson’s trial
Neuro-ophthalmology
Gene therapy breakthrough allows mice to regain sight
Could an eye scan detect signs of Alzheimer's disease?
Vision in Alzheimer's disease: a focus on the anterior afferent pathway
Neurometabolic
Epigenetics, opioids and immune regulation: interviews from SfN17
Jeffrey Iliff: glymphatics, Alzheimer’s and future directions
SfN17: Neurodegeneration and the microbiome – new research highlights
Neuromuscular
New genetic suspects identified for ALS and FTD
Novel discovery in motor neuron disease may pave the way for future treatments
EAN 2017: Guillain-Barré syndrome risk associated with month of birth
Neuropsychiatry
Esketamine receives US FDA approval for treatment-resistant depression
Risk of depression linked to cannabis use in teens
Treasure trove of 269 genes associated with depression identified
Oncology/tumor
SurVaxM for newly diagnosed glioblastoma: an interview with Manmeet Ahluwalia
Recurrent glioblastoma could be effectively treated using pembrolizumab
A peek behind the paper – Charles Cobbs on the Nativis Voyager® for the treatment of glioblastoma
Pain
Could neuropathic pain be treated by modulation of immune cells?
New smartphone application could detect first signs of opioid overdose
The opioid epidemic: could a vaccine prevent addiction and overdose?
Sleep
Tau accumulation in the brain may be linked to sleep apnea
Sleep deprivation: can you catch-up on the weekend?
Night owls vs morning larks: are there differences in brain function?
